Last updated: 11/16/2018 13:40:08
An open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined hepatitis A/hepatitits B vaccine when administered following a 2 dose schedule (0-6 month) and for the first dose, in opposite limbs at month 0, with SmithKline Beecham Biologicals’ measles-mumps-rubella vaccine to healthy children
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined hepatitis A/hepatitits B vaccine when administered following a 2 dose schedule (0-6 month) and for the first dose, in opposite limbs at month 0, with SmithKline Beecham Biologicals’ measles-mumps-rubella vaccine to healthy children
Trial description: An open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined hepatitis A/hepatitits B vaccine when administered following a 2 dose schedule (0-6 month) and for the first dose, in opposite limbs at month 0, with SmithKline Beecham Biologicals’ measles-mumps-rubella vaccine to healthy children
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Usonis V et al. (2005) Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Vaccine. 23 (20):2602-2606.
Medical condition
Hepatitis A
Product
Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine
Collaborators
Not applicable
Study date(s)
November 1998 to October 1999
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-22-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website